Oppenheimer reissued their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research note published on Thursday,Benzinga reports. Oppenheimer currently has a $37.00 price target on the biotechnology company’s stock. A number of other equities analysts have also recently weighed in on the stock. Wall Street Zen raised shares of Sarepta […]

Wedbush restated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Tuesday,Benzinga reports. Wedbush currently has a $38.00 price target on the stock. A number of other research analysts have also recently commented on RNAC. Cantor Fitzgerald raised Cartesian Therapeutics from a “neutral” rating to an “overweight” […]

Wedbush reaffirmed their outperform rating on shares of argenex (NASDAQ:ARGX – Free Report) in a report released on Monday,Benzinga reports. Wedbush currently has a $1,000.00 target price on the stock. A number of other research analysts have also issued reports on the company. Wells Fargo & Company decreased their target price on argenex from $1,317.00 […]

AutoZone (NYSE:AZO – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Oppenheimer in a report released on Tuesday,Benzinga reports. They presently have a $4,300.00 target price on the stock, up from their previous target price of $4,150.00. Oppenheimer’s target price points to a potential upside of 15.04% from the stock’s […]

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $38.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 321.29% from the company’s previous close. RNAC has […]